Figure 2 | Scientific Reports

Figure 2

From: Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection

Figure 2

Construction of full length fusion genes IFNα2b-NS3-LAP and LAP-NS3-IFNα2b through SOE-PCR and OPW-PCR. (A) Amplification of LAP (Lane 1) and IFNα2b (Lane 2) gene with FP1/RP1 and FP2/RP2 primers respectively for fusion gene IFNα2b-NS3-LAP. (B) Amplification of IFNα2b (Lane 1) and LAP (Lane 2) gene with FP1’/RP1’ and FP2’/RP2’ primers respectively for fusion gene LAP-NS3-IFNα2b. (C) Amplification of fusion gene IFNα2b-NS3-LAP (Lane 1) and LAP-NS3-IFNα2b (Lane 2) with insertion of HCV NS3 protease site between fusion partners through SOE-PCR. (D) Appendage of Tag sequence at 5′ end of fusion gene IFNα2b-NS3-LAP (Lane 1) and LAP-NS3-IFNα2b (Lane 2) through OPW-PCR. Lane “M” represents the DNA marker.

Back to article page